© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Collegium Pharmaceutical, Inc. (COLL) stock declined over -0.27%, trading at $33.45 on NASDAQ, down from the previous close of $33.54. The stock opened at $33.34, fluctuating between $32.93 and $33.79 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 22, 2026 | 33.54 | 33.86 | 32.90 | 33.45 | 477.26K |
| Jun 18, 2026 | 33.99 | 34.27 | 33.01 | 33.54 | 631.87K |
| Jun 17, 2026 | 33.27 | 34.67 | 31.69 | 33.68 | 412.39K |
| Jun 16, 2026 | 34.53 | 34.87 | 33.81 | 34.65 | 181.44K |
| Jun 15, 2026 | 34.70 | 35.21 | 34.06 | 34.19 | 408.1K |
| Jun 12, 2026 | 34.69 | 34.93 | 34.32 | 34.64 | 278.46K |
| Jun 11, 2026 | 34.51 | 35.52 | 34.04 | 34.34 | 461.37K |
| Jun 10, 2026 | 34.34 | 35.47 | 34.34 | 34.80 | 374.98K |
| Jun 09, 2026 | 33.71 | 34.85 | 33.60 | 34.40 | 257.98K |
| Jun 08, 2026 | 33.46 | 33.68 | 33.11 | 33.27 | 422.37K |
| Jun 05, 2026 | 33.02 | 34.25 | 33.01 | 33.38 | 333.39K |
| Jun 04, 2026 | 31.61 | 32.81 | 31.61 | 32.69 | 350.12K |
| Jun 03, 2026 | 30.48 | 31.24 | 30.15 | 31.06 | 471.01K |
| Jun 01, 2026 | 33.13 | 33.64 | 31.56 | 31.78 | 512.04K |
| May 29, 2026 | 33.23 | 33.62 | 33.00 | 33.61 | 489.85K |
| May 28, 2026 | 33.48 | 34.30 | 33.06 | 33.37 | 304.69K |
| May 27, 2026 | 33.91 | 35.13 | 33.56 | 33.68 | 377.71K |
| May 26, 2026 | 34.03 | 34.30 | 33.57 | 33.78 | 283.71K |
| May 22, 2026 | 34.55 | 35.01 | 33.98 | 34.07 | 163.82K |
| May 21, 2026 | 33.90 | 34.64 | 33.32 | 34.42 | 206.52K |
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
| Employees | 357 |
| Beta | 0.75 |
| Sales or Revenue | $566.77M |
| 5Y Sales Change% | 0.97% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |